174681-86-8Relevant academic research and scientific papers
A convenient synthesis of 3-substituted pipecolic acid methyl esters
Subramanyam, Chakrapani,Chattarjee, Sankar,Mallamo, John P.
, p. 459 - 462 (1996)
A practical synthesis of the title compounds (3a-c, e) from commercially available 3-hydroxy-2-pyridine carboxylic acid (4) is reported. The key step in the synthetic sequence involves a Pd-catalyzed cross coupling reaction of the triflate 6 with the appr
HEPATITIS C VIRUS INHIBITORS
-
Paragraph 0588-0589, (2017/07/05)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
NOVEL COMPOUNDS
-
Paragraph 0509-0511, (2015/09/22)
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
HCV NS5A replication complex inhibitors. Part 4.1 optimization for genotype 1a replicon inhibitory activity
St. Laurent, Denis R.,Serrano-Wu, Michael H.,Belema, Makonen,Ding, Min,Fang, Hua,Gao, Min,Goodrich, Jason T.,Krause, Rudolph G.,Lemm, Julie A.,Liu, Mengping,Lopez, Omar D.,Nguyen, Van N.,Nower, Peter T.,O'Boyle, Donald R.,Pearce, Bradley C.,Romine, Jeffrey L.,Valera, Lourdes,Sun, Jin-Hua,Wang, Ying-Kai,Yang, Fukang,Yang, Xuejie,Meanwell, Nicholas A.,Snyder, Lawrence B.
, p. 1976 - 1994 (2014/04/03)
A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging f
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 129, (2012/02/15)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 129-130, (2011/06/16)
The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 124-125, (2011/07/07)
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 139, (2010/12/26)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Hepatitis C Virus Inhibitors
-
Page/Page column 71, (2010/10/19)
This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 182-183, (2010/12/26)
This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
